CCL21-CCR7 blockade prevents neuroinflammation and degeneration in Parkinson’s disease models

Authors:

Abstract
Parkinson’s disease (PD) is a progressive degenerative disease of the central nervous system associated with neuroinflammation and microglial cell activation. Chemokine signaling regulates neuron-glia communication and triggers a microglial inflammatory profile. Herein, we identified the neuronal chemokine CCL21 as a major cause of microglial cell imbalance through the CCR7 receptor pathway with therapeutic implications for PD. In humans, we found that CCL21 transcript expression was increased in dopaminergic neurons (DANs) of the substantia nigra in PD patients. CCL21 and CCR7 expressions were spatially associated with brain regional vulnerability to synucleinopathies, as well as with the expression of microglial activation, neuroinflammation, and degeneration-related genes. Also, in mouse models of PD, we showed that CCL21 was overexpressed in DANs in vivo and in vitro. Mechanistically, neuronal CCL21 was shown to regulate microglial cell migration, proliferation, and activation in a CCR7-dependent manner through both canonical (PI3K/AKT) and non-canonical (ERK1/2/JNK) signaling pathways. Finally, we demonstrated that navarixin, a clinically relevant chemokine inhibitor with high affinity for the CCR7 receptor, could block CCL21 effects on microglia and prevent neurodegeneration and behavioral deficits in two mouse models of PD induced with either α-synuclein oligomers (αSynO) or 3,4-dihydroxyphenylacetaldehyde (DOPAL). Altogether, our data indicate that navarixin blocks CCL21/CCR7-mediated neuron-microglia communication and could be used as a therapeutic strategy against PD. DOPAL treatment induces neurodegeneration both in vitro and in vivo and triggers PD-like behavior in mice. CCL21 is overexpressed in PD patients and DOPAL-induced mouse model. CCL21-CCR7 mediates microglial cell activation and neuroinflammation in mice. Navarixin inhibits the activation of CCR7 by CCL21 in microglial cells, thereby inducing neuroprotection both in vitro and in vivo and preventing PD-like behavioral deficits in mice.
Funding Information
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • H2020 European Research Council (834161)
  • Instituto Nacional de Neurociência Translacional
  • Programa de Pós-Graduação em Ciências Morfológicas
  • Coopération Universitaire et Scientifique avec le Brésil

This publication has 118 references indexed in Scilit: